Karolinska University Hospital to purchase Elekta’s Leksell Gamma Knife Icon

New system is most precise stereotactic radiosurgery system on the market
STOCKHOLM, November 25, 2015 – By acquiring Elekta’s (EKTA-B.ST) latest
generation intracranial stereotactic radiosurgery system, Leksell Gamma Knife®
Icon™, Stockholm’s Karolinska University Hospital will be able to offer the
benefits of precision cranial radiosurgery to more patients with a wider variety
of tumor types and sizes.

The hospital was instrumental in the history of radiosurgery as Lars Leksell,
Elekta’s founder, received his medical degree at Karolinska Institutet, then
went on to develop the original Leksell Gamma Knife® system while serving as a
professor of neurosurgery there.

Gamma Knife Icon is the sixth generation of the company’s Leksell Gamma Knife
system, a technology that has been in use worldwide and continually evolving
since the 1980s. With stereotactic imaging, online Adaptive DoseControl™, ultra
-precise dose delivery and the availability of frameless treatments, Icon is
capable of treating virtually any target in the brain, regardless of type,
location or volume.

Tomas Puusepp, Elekta’s President and CEO, says: “We are happy that Karolinska
University Hospital has chosen the most advanced Leksell Gamma Knife
radiosurgery system when they open the doors to their new hospital, New
Karolinska Solna. We hope to continue working with Karolinska to provide them
with the best solutions available as they strive to improve patient care.”

For more information on Leksell Gamma Knife Icon, visit www.careforthebrain.com

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on November 25, 2015.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com